01About

About
Cyrano Therapeutics

Cyrano Therapeutics is a private, venture-backed clinical stage regenerative medicine company. Since our foundation, we have been working diligently to develop a therapy for people struggling with the loss of smell and flavor.

Board of Directors
Meet Our Team

Rick Geoffrion

President and CEO

More than 35 years of management experience with pharmaceutical and medical devices. Rick has led the foundation and/or reorganization of 7 healthtech companies; several have changed the course of medical therapy.

R. I. Henkin, MD

Cofounder and Chief Scientific Advisor

Founder and Director of The Taste and Smell Clinic, Washington, DC, Dr Henkin has spent the last 40 years devoted to the diagnosis and treatment of taste and smell disorders as evidenced by over 1000 peer-reviewed publications on the subject.

Taka Koda

Partner, Remiges Ventures

Taka Koda is Partner at Remiges Ventures, a US-Japan venture capital firm focusing on therapeutics. With over 20 years of business development and venture investment experience, he founded and served in board capacities and management roles for start-up companies as well as providing advisory services for business groups. Previously, he was a member of Mitsui’s Private Equity group for venture investments and fund operations both in the US and Japan.

Gerry Brunk

Managing Director, Lumira Ventures

Gerry Brunk is a cofounder and Managing Director at Lumira Ventures, a North American healthcare venture capital firm. Prior to beginning his investing career in 2002, Mr Brunk founded and served in a variety of management and board capacities at several venture capital-funded healthcare companies. Previously, he was an engagement manager in the healthcare practice of The Boston Consulting Group and a member of the investment banking group of Credit Suisse First Boston.

John Kollins

Cofounder and CEO of Satsuma Pharmaceuticals (STSA)

John Kollins has more than 30 years of biopharmaceutical industry experience and currently serves as President and Chief Executive Officer of Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company he cofounded to develop STS101 (dihydroergotamine [DHE] nasal powder), a novel investigational therapeutic product candidate for the acute treatment of migraines.

Rick Geoffrion

President and CEO

More than 35 years of management experience with pharmaceutical and medical devices. Rick has led the foundation and/or reorganization of 7 healthtech companies; several have changed the course of medical therapy.

R. I. Henkin, MD

Cofounder and Chief Scientific Advisor

Founder and Director of The Taste and Smell Clinic, Washington, DC, Dr Henkin has spent the last 40 years devoted to the diagnosis and treatment of taste and smell disorders as evidenced by over 1000 peer-reviewed publications on the subject.

Ron Kuppersmith, MD

Chief Medical Advisor

Former President of the American Academy of Otolaryngology–Head and Neck Surgery. Currently the CEO of ENT Specialty Partners, former Board member of Spirox (acquired by Entellus), former Board advisor of Entellus (acquired by Stryker), and former Board Member of Arrinex (acquired by Stryker).

Jerry Andry

VP, Clinical and Regulatory Affairs

More than 20 years of experience managing clinical and regulatory pathways in respiratory therapeutics at Hikma Pharmaceuticals and Boehringer Ingelheim. Products include generic Advair Diskus as well as branded and generic nasal sprays.

John Carlos Diaz

Clinical Operations

Clinical research leader with more than 20 years of combined preclinical and clinical operations experience; currently leads a team of biostats, medical writing, medical oversight, and clinical field staff.

We’d like to hear from you!

For more information about Cyrano, please don’t hesitate to contact us.

    *Required fields.